Bleomycin and Tetracycline in Malignant Pleural Effusions: a Review
Overview
Authors
Affiliations
Pleural effusions remain a distressing and symptomatic problem in cancer patients. Once a malignant pleural effusion is diagnosed, appropriate therapy may provide symptomatic relief and improved quality of life. In this paper, we review previous data on chest tube drainage and pleurodesis in patients with malignant pleural effusions. A comparison is made of the various sclerosing agents. Specifically, recent data from a study comparing bleomycin and tetracycline as sclerosing agents are discussed. These data show a clear advantage with bleomycin at both 30-day and 90-day end points--30-day recurrence, 36% versus 67%; 90-day recurrence, 30% versus 53%.
Khater A, Hassan A, Farouk O, Sinbel A, Saleh S, Abdelaziz M Eur J Breast Health. 2023; 19(2):134-139.
PMID: 37025572 PMC: 10071883. DOI: 10.4274/ejbh.galenos.2023.2022-11-1.
Gaafar R, Abdel Rahman A, Aboulkasem F, El Bastawisy A Ecancermedicalscience. 2014; 8:424.
PMID: 24834119 PMC: 4004388. DOI: 10.3332/ecancer.2014.424.
Seto T, Ushijima S, Yamamoto H, Ito K, Araki J, Inoue Y Br J Cancer. 2006; 95(6):717-21.
PMID: 16940982 PMC: 2360516. DOI: 10.1038/sj.bjc.6603319.
Hwang J, Song K, Park S, Lim T, Kwon K, Goo D Korean J Radiol. 2005; 6(2):94-101.
PMID: 15968148 PMC: 2686426. DOI: 10.3348/kjr.2005.6.2.94.
Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer.
Barbetakis N, Vassiliadis M, Kaplanis K, Valeri R, Tsilikas C BMC Palliat Care. 2004; 3(1):4.
PMID: 15357871 PMC: 520817. DOI: 10.1186/1472-684X-3-4.